Literature DB >> 32338053

Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.

Muhammed Osman Corbali1, Ahmet Emre Eskazan2.   

Abstract

Entities:  

Keywords:  AML; MDM2 inhibitor; TP53; acute myeloid leukemia; idasanutlin; relapsed or refractory

Year:  2020        PMID: 32338053     DOI: 10.2217/fon-2020-0218

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  1 in total

1.  In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma.

Authors:  Chiao-En Wu; Chiao-Ping Chen; Yi-Ru Pan; Shih-Ming Jung; John Wen-Cheng Chang; Jen-Shi Chen; Chun-Nan Yeh; John Lunec
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.